Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | ARG1 | P05089 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038961 | 0.90 | ALDH1A1 (0.51) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL14031929 | 0.85 | ALDH1A1 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10856186 | 0.84 | CA12 (0.51) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL24107635 | 0.84 | CA12 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL29458127 | 0.84 | CA12 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18991291 | 0.83 | ARG1 (0.58) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL27220883 | 0.81 | ALDH1A1 (0.67) | CA12CA1CA2CA9ALDH1A1 | |
| Bicarbonate SCHEMBL22832269 | 0.80 | ALDH1A1 (0.83) | CA12CA1CA2CA9ALDH1A1 | |
| Bicarbonate SCHEMBL22832272 | 0.80 | ALDH1A1 (0.83) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL812138 | 0.80 | ALDH1A1 (0.51) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| EP-1968945-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077510-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | CA12 4051/4885CA1 4072/4885CA2 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.